Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
Alex Brill joined CNBC’s “Squawk Box” to discuss the IRS’ attempt to crack down on the tax gap.
Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.